Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand ...

By influencing multiple body systems simultaneously, tirzepatide offers a powerful approach to managing both diabetes and ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...